Thirty percent of males af¯icted with erectile dysfunction (ED) do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable rigidity compared to oral drugs. This paper provides both a historical and current perspective on intracavernosal therapy and reviews the popular injectable therapeutic agents that are currently used for the treatment of ED. Emphasis is placed on the ef®cacy, mechanism of action and side effect pro®les of approved and experimental injectable pharmacotherapy for ED.
History of intracavernosal pharmacotherapy
It is generally acknowledged that the onset of intracavernosal pharmacotherapy began with the publication by Virag in 1982 concerning the erection-including properties of papaverine. 1 Further important early publications in this ®eld described the erectile potency of the alpha-adrenoceptor blockers phenoxybenzamine and phentolamine 2 and the combination of papaverineaphentolamine for autoinjection of the cavernous bodies. 3 In fact, the work of Zorgniotti and Le¯eur 3 marked the breakthrough of self-injection therapy as a completely new tool in the management of male impotence. One year later, at the Second World Meeting on Impotence in Prague, PGE 1 (alprostadil) was introduced for self-injection therapy, by both Adaikan 4 and Ishii. 5 Two years later, these favorable preliminary reports on alprostadil were con®rmed in larger clinical trials by Porst and Stackl, respectively. 6, 7 Alprostadil has since become the global leader in intracavernosal pharmacotherapy. It is marketed by two different companies as alprostadil sterile powder (Caverject 1 , Pharmacia & Upjohn) and alprostadil alfadex (Edex 1 , Viridal 1 , Schwarz Pharma AG); both agents exhibit an identical ef®cacy-and side-effect spectrum.
Parallel to the development of monotherapy with alprostadil, the trimix combination of PGE 1 a papaverineaphentolamine began to gain broad acceptance following the publication of Goldstein in 1990, especially in the USA. 8 In 1989, the relatively selective alpha 1 -adrenoceptor blocker moxisylyte (thymoxamine) was introduced by Buvat et al. 9 Moxisylyte was ®rst marketed in France as Icavex 1 and Erecnos 1 and the latter has since been withdrawn due to unpro®table sales rates. The erectile potential of other vasoactive drugs, eg, calcitonin-gene-relatedpeptide (CGRP), linsidomine (syn. SIN-1), vasoactive intestinal polypeptide (VIP) or sodium nitroprusside, was temporarily publicised but none of the cited compounds gained market approval status. 10 ± 15 In this context, two exceptions deserve mention. Firstly, the combination of papaverineaphentol-zamine (Androskat 1 ) was of®cially approved by the local health authorities of several countries and is marketed in the Benelux and German-speaking countries of Europe. Secondly, the combination of VIPaPhentolamine (Invicorp 1 ), originally studied by Gerstenberg et al in 1992, was of®cially approved in Denmark but not marketed and can be prescribed on an individual`named' basis in UK. 16 Pharmacological considerations of marketed intracavernosal vasoactive drugs (Table 1) phosphodiesterases (PDE 1 to PDE 10 ), administration of papaverine results in cAMP or cGMP accumulation. Papaverine also appears to exert inhibitory effects on L-type voltage-dependent Ca 2 channels and on angiotensin II secretion. 17, 18 Phentolamine Phentolamine represents a non-selective alpha 1 ± 2 -adrenoceptor blocker with impact both on pre-and post-synaptic alpha-adrenoceptors. In the caninemodel, phentolamine administration resulted in a 50 ± 100% increase of penile arterial blood¯ow without an additional in¯uence on the venoocclusive mechanism. 19 Beyond this dominant pharmacological action, it was shown that phentolamine has potassium channel opening, endothelin antagonist and direct nitric oxide (NO)-synthase activating properties. 20, 21 Alprostadil (PGE 1 )
Proven pharmacological and biological effects of alprostadil in the context of ED are:
(1) Stimulation of adenylate cyclase with generation of 3 H 5 H -cAMP. 22 (2) Inhibition of noradrenaline release at alpha 1 -adrenoceptors via presynaptic prostaglandin receptors. 23 (3) Inhibition of angiotensin II secretion. 18 (4) Stimulation of maxi-K ion channels resulting in membrane hyperpolarization. 24 (5) Neuromodulatory activities on the medial preoptic area. 25 (6) Inhibition of the transforming growth factor b 1 (TGF-b 1 ) resulting in anticollagen and therefore anti®brotic effects. 26 In addition, prostaglandins and especially PGE 1 have demonstrated other biological effects including: 27 decrease of low density lipoprotein (LDL) receptor activity with LDL degradation, positive effects on rheologic properties and blood viscosity, decrease of cholesterol deposition into the arterial wall and inhibition of platelet aggregation resulting in atherosclerosis prevention, inhibition of noradrenaline-induced lipolysis, and positive effects on cellular nutritive metabolism of ischemic tissue due to decrease of the lactate to pyruvate ratio.
Moxisylyte (thymoxamine)
Moxisylyte has alpha 1 ± 2 -receptor blocking properties with preference for alpha 1 -adrenoceptors. 9, 28 Moxisylyte is a pro-drug that is immediately converted to ®ve metabolites, four of which exhibit biological activities. 28 
Vasoactive intestinal polypeptide
Vasoactive intestinal polypeptide (VIP) is a naturally occurring neurotransmitter which is co-localized with NO at the nonadrenergic, noncholinergic (NANC) nerve-terminals in cavernous tissue. 29 VIP stimulates adenylate cyclase and results in the generation of 3
H 5 H -cAMP. In animal studies, intracavernosal VIP induced tumescence and partial erection, which was primarily due to decreased penile venous out¯ow and to a minor extent, increased arterial in¯ow. 30 Clinical results of self-injection therapy with marketed vasoactive drugs Papaverine Papaverine is extremely stable in solution and loses only 10% of its potency over a 4 y period. Commercial papaverine solutions have a low pH between 3 31 Papaverine is extensively metabolised in the liver. Reported ef®cacy rates with dosages between 30 and 110 mg varied between 27 and 78% and were dependent on dosage and the patient population investigated. 27, 32, 33 A literature analysis of 19 publications that included 2181 patients overall demonstrated that papaverine produced an average response rate of 61% in in-of®ce testing. 27 The most important side-effects were priapisms in 3 ± 18.5%, which mostly occurred during the titration phase. Fibrotic alterations were seen in 5 ± 30% of patients with an average of 5.7% in 15 retrospective studies (Table 2) . 27, 32, 33 In long-term self-injection trials, papaverine produced liver enzyme elevations in 1.6% of patients, evidence of hepatotoxic potential. 27 In animal studies, papaverine resulted in the highest ®brosis-rate among all the investigated vasoactive drugs. For this reason, monotherapy with papaverine has been discontinued in most industrialized countries. 34, 35 However, due to its considerably low cost, self-injection monotherapy with papaverine still continues in many developing countries.
Papaverineaphentolamine (Androskat 1 )
The combination of papaverineaphentolamine gained world-wide popularity with the publication of Zorgniotti and Le¯eur in 1986. 3 The pH values of marketed Androskat 1 solution varies between 3.1 and 3.5 and is stabile for 2 ± 3 y. The current cost in Europe for 5Â2 ml ampoules containing 15 mg papaverine and 0.5 mg phentolamine per ml is approximately 60 US dollars. Combining the 3 H 5 H cAMPacGMP accumulating effects of papaverine and the alpha-adrenoceptor blocking properties of phentolamine results in an increased average response-rate up to 60 ± 70% observed during in-of®ce testing. 36 With home use, response rates as high as 90% have been reported. 37 Prospective long-term comparison studies of papaverine alone to the mixture of papaverinea phentolamine conducted under good clinical practice guidelines are not available. In valuable retrospective studies that have considered important issues related to self-injection therapy, ie, success-, side-effect-and drop-out rates, global ef®cacy rates were 68.5% in diagnostic use in 3016 assessed patients. 27 Frequent side-effects were similar to those of papaverine. Priapisms were reported in 6 ± 15% and ®brotic alterations occurred in an average of 12.4% of patients treated (see Table 2 ), although in some studies, ®brotic complications occurred in considerably higher percentages of 18 ± 57%. 27,37 ± 40 Hepatotoxic effects with elevation of liver enzymes were reported in an average of 5.4% (43a799) of patients in one review of varied publications. 27 Alprostadil syn. PGE 1 (Caverject 1 and Edex 1 or Viridal 1 )
The pharmacologic pro®le of alprostadil is summarized in Table 6 . Intracavernously (i.c.)-injected alprostadil may be partially metabolized by the enzymes of the cavernous tissue and although considerable amounts reach the systemic circulation, it is metabolized during the passage through the lung. 41, 42 It is therefore not surprising that the half-life of i.c.-injected PGE 1 is only 30 ± 60 sec.
In contrast to papaverine or to the papaverinea phentolamine combination, large world-wide prospective studies have been conducted in accordance with good clinical practice guidelines for both alprostadil preparations (alprostadil sterile powder ± Caverject 1 and alprostadil alfadex ± Viridal 1 or Edex 1 ) and long-term follow-up of 4 ± 5 y is available. 43 ± 46 A review of these large studies shows that the ef®cacy-rate of alprostadil during in-of®ce titration varied between 70 and 75% in more than 10 000 patients. 27 Meanwhile, the author's experience in more than 12 000 patients with ED undergoing a 20 mg intracavernosal PGE 1 injection test resulted in an in-of®ce ef®cacy rate of 72%, con®rming the data from the literature.
In a variety of prospective self-injection trials, the success-rates (de®ned as successful coitus per injection) varied between 89 and 96%; this is higher than any reported ef®cacy rate among all the available marketed vasoactive drugs (Table 3) . 43, 46 Typical side-effects with alprostadil self-injection therapy are the occurrence of penile pain in 8 ± 52%, however, with long-term follow-up and individual dose adjustment, pain-rates decreased to 1 ± 11%. 45, 46 Priapisms were almost exclusively observed in the titration-phase and varied between 0.25 and 1% (Table 2) . 27, 43, 46 In the two major trials with both alprostadil-preparations, penile ®brotic alterations were encountered in 7.5 ± 11.7% of patients during the course of the 4 ± 5 y of long-term follow-up. 45, 46 The prevailing majority of ®brotic alterations were small nodules which did not interfere with erectile function or vaginal penetration (Table 4) . Between 33 and 47% of these penile ®broses healed spontaneously, suggesting that the incidence of persistent penile ®broses in patients on long-term self-injection therapy is between 5 and 7%. 43, 44, 46 Similar to self-injection trials with all vasoactive drugs, the drop-out rates in the alprostadil trials were relatively high, eg, 55% after 18 months in the alprostadil-sterile powder (Caverject 1 ) study and 54% after 24 months in the alprostadil-alfadex (Viridal 1 ) trial. 44 ± 46 After 4 y of follow-up, 33% of patients continued therapy with alprostadil alfadex and 22% continued regular therapy with alprostadil sterile powder after 5 y of follow-up. 45, 46 The satisfaction-rates of both male and female partners in the group who continued were high and ranged between 91 and 95%. 46 In addition, between 78 and 89% of patients and their female sexual partners stated that the self-injection therapy markedly improved both the self-esteem of the af¯icted males and the partner-relationships (Table 5) . 46 Moxisylyte (Icavex 1 )
Moxisylyte (Table 7) , an alpha-adrenergic blocking compound with preference of alpha 1 -adrenoceptors was investigated in comparison to alprostadil alfadex in a prospective trial. 47 The ef®cacy rates for 20 mg alprostadil were 75% (56a75) con®rmed with a positive Buckling-test and increased to 85% when the same patients performed self-injection therapy at home. The comparable ef®cacy rates after 20 mg moxisylyte were 40% (32a81) for the Buckling-test and 61% (37a61) for the self-injection group. Claimed advantages of moxisylyte in other studies were the low risk of priapism (`1%) and ®broses (`2%) but these low side-effect rates were put into perspective by low ef®cacy rates if compared to alprostadil or papaverineaphentolamine. 47 ± 49 In addition, in all published moxisylyte trials, clinically relevant drops in blood pressure accompanied by orthostatic symptoms and dizziness were described in 5 ± 8% of patients. 48, 49 Moxisylyte was originally marketed under two different trade names ± Icavex 1 and Erecnos 1 , but due to its low market acceptance, the latter one was withdrawn some time ago.
VIPaphentolamine combination (Invicorp 1 )
As VIP alone injected i.c. in volunteers did not result in rigid erections, a combination of VIP and phentolamine was developed for self-injection therapy (Table 8) . 13, 50 In an early prospective 6 month trial with 30 mg VIP and 0.5 ± 2 mg phentolamine in 52 patients who underwent a total of 1380 scheduled injections, no priapisms, pain or ®broses were reported. 16 In a larger prospective trial with 289 patients (mean age 58.5 y), 77% responded with grade 3 erections, considered by the investigators to be suf®cient for intercourse. 51 In this study, two priapisms (0.6%) were observed. Final results of the UK multicenter placebo-controlled Invicorp 1 -trial were published by Sandhu in 1999 and are summarized in Table 9 . 52 In this prospective trial, the total drop-out rate (calculated from the date of ®rst-patient-in and last-patient-out after 6 months was 65.5% (199a304) and was thus considerably higher than in all other alprostadil injection trials. 43, 46, 52 There were no comments about the reasons for this high drop-out rate. 
The greatest advantage of the Invicorp 1 preparation is its availability in a ready-for-use automatic single injection device equipped with a 29 gauge needle (Figure 1 ). This device may be preferred by many patients because the necessity to reconstitute alprostadil preparations and the requirement for manual injections is avoided.
The author's personal experiences with the VIPaphentolamine combination are limited to 25 patients in whom the Invicorp 1 1a2-combination was compared against Alprostadil 20 mg (Caverject 1 ). In this small series, the response rates for Invicorp 1 were 60% (15a25) compared to 72% (18a25) for Caverject 1 . The automatic injection device for the Invicorp 1 -combination represents a very convenient and user-friendly solution for intracavernosal injections. As mentioned above, Invicorp 1 is approved but not marketed in Denmark and can be prescribed on an individual namedpatient basis in the UK. The dosages for Invicorp 1 1 are 25 mg VIPa1 mg phentolamine or 2 mg phentolamine for Invicorp 1 2, respectively.
Clinical experiences with experimental vasoactive drugs (Table 10)

Linsidomine (SIN 1)
Linsidomine belongs to the family of NO-donors and generates NO non-enzymatically, subsequently resulting in stimulation of guanylate cyclase and ultimately, 3
H 5 H -cGMP accumulation. Very promising 
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results with success-rates of up to 69% (78a113) were reported by authors of one study group, 11,53 but could not be con®rmed by others. 12, 54 In a small comparative trial conducted by the author in 40 patients, the ef®cacy-rates (partial or full rigidity) after 1 mg SIN-1 were 35% compared to 82.5% after alprostadil 20 mg. 12 Due to these signi®cantly lower ef®cacy-rates with admittedly low side effect rates, the compound was not pursued further and did not enter a full clinical trial program toward market development.
Sodium nitroprusside
Sodium nitroprusside, a NO-donor similar to SIN-1 was evaluated in a comparative trial with alprostadil. 15 In a total of 95 patients, 49% responded with partial and 15% with complete rigidity to 300 ± 400 mg doses of nitroprusside compared to 54% and 20%, respectively, after 20 mg alprostadil. With nitroprusside doses of 600 mg, global response rates of 84% were achieved. Because alprostadil produced better response rates and sodium nitroprusside was incriminated with hypotonic blood pressure reactions in up to 15% of patients, this compound did not enter the phase of multicenter trials.
Calcitonin gene related peptide combined with PGE 1
Calcitonin gene related peptide (CGRP) a potent vasodilator, increased penile blood¯ow and resulted in tumescence but not rigidity when given intracavernously in dosages of 500 mg. 10 In a population of 65 patients, of whom 91% were nonresponders to the papaverine (30 mg)aphentolamine (1 mg) combination, CGRP (5 mg) combined with PGE 1 (10 mg) produced rigid erections in 55%. 55 In another study performed by Schwarzer et al, 30% of patients who failed 40 mg PGE 1 or 80 mg papaverine or the combination of 60 mg papaverine plus 2 mg phentolamine obtained rigid erections following treatment with 5 mg CGRP plus 20 mg PGE 1 . 56 Since these reports which appeared nearly a decade ago, no further reports on the validity and safety of the CGRPaPGE 1 combination have been published.
From this we can surmise that no pharmaceutical company opted to bring this combination product through the rigorous path toward market approval.
Triple-drug (trimix) ± papaverineaphentolaminea PGE 1
Combining the three vasoactive drugs: papaverine, phentolamine and PGE 1 allows one to reduce the dosages of the individual compounds and therefore to lower the risks of side-effects attributed to the respective single drugs while increasing ef®cacy rates. Reported dosages of single compounds in several publications varied between 4.4 and 15 mg papaverine, 0.15 and 0.5 mg phentolamine, and 1.5 and 20 mg PGE 1 per ml. 8, 57, 58 Response rates with the trimix combination in non-selected patients with ED approached 80 ± 90% and were thus 10 ± 15% higher than after 20 mg alprostadil monotherapy. 57, 59 Because rigid erections following trimix administration were achieved in 50 ± 62% of socalled non-responders, some authors suggested that trimix would be useful rescue therapy for nonresponders to monotherapy with alprostadil or the combination of papaverineaphentolamine. 8, 58 In two prospective trials the trimix combination was preferred by 46 ± 67% of patients compared to 19 ± 23% for the approved alprostadil sterile powder (Table 11) . 60, 61 In the author's hands, the trimix combination produces a response in 30 ± 40% of non-responders to 40 mg alprostadil. It can easily be easily be prepared by mixing one ampule of Androskat 1 (30 mg papaverinea1 mg phentolamine) with 10 ± 20 mg Caverject 1 . Within the context of this extemporaneous reconstitution, it must be considered that the stability of the three drug combination varies with a 30% degradation of the PGE 1 -concentration within 60 days. 62 The trimix self-injection therapy should be reserved for patients who do not respond to alprostadil or for those who experience painful erections after alprostadil alone. Trimix is principally associated with the same side-effect and riskpro®le of papaverine and phentolamine, especially in terms of priapism and ®brosis. Special topics on self-injection therapy (Table 12) Patients treated concurrently with anticoagulants
The safety of vacuum-therapy and self-injection therapy was compared in a cross-over study of 33 patients being treated with warfarin. 63 In only 11 (1.6%) of 706 documented vacuum applications and three (0.5%) of 605 self-injections, ecchymoses of the penile skin were recorded in patient diaries, indicating that the risk of bleeding, both in vacuum therapy and self-injection therapy, is not higher in the group receiving anticoagulants than it would be in a normal patient population. In the author's clinical practice, following 10 patients treated with the anticoagulant marcoumar for a number of years, no severe bleeding complications have been observed. Therefore, patients treated with anticoagulants (either platelet aggregation inhibitors or warfarinamarcoumar) do not represent contraindications for self-injection therapy provided they are carefully instructed in self-injection techniques and use thin (27 ± 30 gauge) needles.
Transplant recipients
A study conducted with 26 renal transplant patients did not reveal any increased risk for self-injection therapy, 64 corroborating the author's own experiences with three transplanted patients (two kidneys, one heart).
Patients with diabetes mellitus
In a comparative trial among 16 diabetic and 29 nondiabetic patients with a mean follow-up of 9.4 months and an average injection frequency of three per month, focal ®brotic alterations were more frequently observed in the diabetic cohort (25%) compared to 3% in the control-group. 65 This series supports the author's impressions that insulin-dependent diabetics are more prone to the occurrence of ®brosis than other patient subsets.
Managing complications of self-injection therapy
Priapism
It is generally accepted that priapisms lasting b 6 h should be interrupted to prevent tissue damage. Electromicroscopical investigations by Spycher (1986) suggested that irreversible tissue impairment may be occurring after 12 ± 18 h. 66 According to the author's personal observation of more than 150 patients with drug-induced priapisms, direct injection of a sympathomimetic antidote is suf®cient if the priapism did not last longer than 12 h. In priapisms longer than 12 ± 18 h duration, it is reasonable to evacuate the entrapped hypoxemic blood with i.c. insertion of a butter¯y cannula, wait 10 ± 15 min until reoxygenation has established, then inject the adrenergic antidote if it is still deemed necessary. Among all the available adrenergic drugs, etilefrine and phenylephrine have the least impact on cardiac b-receptors and are therefore probably the safest choice. 67 The recommended dosages are 5 ± 20 mg for etilefrine or 0.1 ± 0.5 mg for phenylephrine. It is reasonable to start with a low dosage and massage the penis between the ®ngers after removal of the needle to promote circulation of the injected antidote within the entrapped blood in the cavernous bodies. If the erection persists after 15 min, a repeat dosage should be injected in to the opposite cavernous body. If this injection also fails, evacuation is advisable. After the antidote injection, blood pressure readings must be taken to detect blood pressure increases, which are successfully treated by oral or fast-acting sublingual nifedipine.
Fibrosis
As described earlier, most ®brotic alterations that develop during the course of self-injection therapy are mild or moderate and concern small nodules in the tunica albuginea or in the penile septum (Table  4) . In this case, the patient should be re-instructed in the correct injection technique and taught to avoid the affected area when performing future injections. In the event real ®brotic plaques with or without penile curvature develop, self-injections should temporarily be discontinued for 3 ± 4 months. Following reassessment by an in-of®ce intracavernosal injection test, the option of surgical interventions (corporoplasty or penile implant) versus continuation of injection therapy should become evident. If corporoplasty seems unavoidable, sexual intercourse may be resumed after 3 ± 4 months, supplemented again with self-injection or transurethral therapy. Alternatively, and preferably, oral sildena®l (Viagra 1 ) or apomorphine SL, may be used, provided that these novel oral compounds prove to be effective in these patients.
Future role of self-injection therapy versus oral drug therapy
There is no question that, since ef®cacious oral drug therapy like sildena®l has become available, management of male impotence has dramatically improved. Notwithstanding the observation that most ED patients can be managed by oral drug therapy, there will be a considerable number of candidates for self-injection therapy. These candidates will likely be represented in the following categories:
(1) About 15 ± 20% of all patients with erectile dysfunction show contraindications to sildena®l-like nitrate or NO-donor medications, ie, those with severe cardiac disease or those treated with antihypertensive polypharmacotherapy. (2) According to the author's personal experiences, about 15% of alprostadil responders are sildena®l non-responders. In particular, this observation will be true in patients who are likely to have cavernous nerve impairment (pelvic surgery or trauma, insulin dependent diabetes). (3) According to the author's personal experiences and recent reports, 30 ± 40% of patients satis®ed with long-term self-injection therapy will stay on this therapy despite sildena®l (Table 13 ). 68 (4) In a considerable number of patients ($ 50%) who do not respond to either sildena®l or injection-therapy, the combination of both methods has the potential to rescue these patients and preserve them from vacuum therapy or penile implants. 70 
